Vol 3 (April 25, 2025): AME Clinical Trials Review

Lessons from FOWARC: moving towards the more precise use of radiation therapy in the era of total neoadjuvant therapy

Stereotactic ablative radiotherapy as a novel strategy in patients with oligometastatic hepatocellular carcinoma

Finding the RIGHT Choice in patients with clinically aggressive ER-positive HER2-negative metastatic breast cancer

Empowering treatment: insights from 35 months follow-up highlight the benefits of cemiplimab monotherapy and continued immunotherapy plus chemotherapy beyond progression in advanced non-small cell lung cancer patients with high PD-L1 expression

Patritumab deruxtecan: advancing the treatment landscape for EGFR-resistant non-small cell lung cancer

Emerging role of circulating tumor DNA as a predictive biomarker in consolidation immunotherapy for unresectable stage III NSCLC

Revumenib: a new potential targeted therapy for KMT2A-rearranged acute leukemia

Intravascular imaging guided optimization in complex percutaneous coronary intervention (PCI)—does clinical presentation matter?

Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?

A SMART-er approach to upfront unresectable pancreatic adenocarcinoma